




Name	Sophia Adamia	
Current Position	Member of the Faculty of Medicine, Department of Medicine, HMS; Scientific Director of CMCF, BIDMC.	
Country	USA	
Major Field	Hematology Oncology, Translational Medicine	

Educational Background

11/2006	Doctor of Philosophy	Oncology	Faculty of Medicine and Dentistry, University of Alberta; Cross Cancer Institute/Alberta Health Services
---------	----------------------	----------	--

Certification:

01/2005	Bioinformatics	Certification- workshop	Bioinformatics Canada/ Canadian Genetics Diseases Network
06/2016	Bioethics	Intensive Bioethics training	The Kennedy Institute of Ethics, Georgetown University
03/2022	Health Care Ethics Consultation	Certification- workshop	Harvard Medical School, Center for Bioethics

Postdoctoral Training:

2007-2012	Postdoctoral Research Fellow	Medical Oncology/ Division of Hematologic Neoplasia	Dana-Farber Cancer Institute (DFCI) and Harvard Medical School (HMS)
-----------	------------------------------	---	--

Professional Experience

Faculty Academic Appointments:

11/2013-11/2019	Instructor of Medicine	Medical Oncology/ Division of Hematologic Neoplasia	DFCI and HMS
11/2019-11/2021	Associated Professor	Institute of Medical and Public Health Research	Ilia State University (ISU), Tbilisi, Georgia
12/2021-	Professor	Institute of Medical and Public Health Research	ISU
05/01/2022-	Member of the Faculty of Medicine (Assistant Professor)	Medicine/ Division of Hematology/Oncology	HMS and Beth Israel Deaconess Medical Center (BIDMC)

Appointments at Hospitals/Affiliated Institutions:



09/2019-04/2022	Senior Scientist/group leader	Medical Oncology (Division Hem/Oncology)	Dana-Farber Cancer Institute
04/2022-present	Scientific Director of CMCF	Medicine /Division Hem/Oncology	BIDMC

Other Experience and Professional Memberships

09/03-09/06	Student-Scientist	National Research Council Canada, National Institute for Nanotechnology (NINT), Edmonton, Alberta, Canada
2015	Short-term consulting	Agios Pharmaceuticals

International

2018-2019	Advisory board	Institute of Medical Research/Ilia State University, Georgia
	2018-2019	International member
2020-	Curriculum committee for MD/PhD program	School of Medicine/ Ilia State University, Georgia
	2020-	International advisor for PhD program

Professional Societies:

2000-2001	Canadian Society of Immunology (CSI)	Member in training
2002-2003	American Society for Microbiology (ASM)	Member in training
2001-2006	American Society of Hematology (ASH)	Member in training
2008-	American Society of Hematology (ASH)	Active Member #1015226
2007-	American Association for Cancer Research (AACR)	Member #147556
2008-2015	American Association for Clinical Oncology (ASCO)	Member #82615
2016-	International Myeloma Society (IMS)	
2017-present	The RNA Society	Full (Author) Member # 84-1222776

Main Scientific Publications

- Goss GG, **Adamia S**, Galvez F. Peanut lectin binds to a subpopulation of mitochondria-rich cells in the rainbow trout gill epithelium. *Am J Physiol Regul Integr Comp Physiol*. 2001;281:R1718-5. ISSN 0363-6119.
- Adamia S**, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulinemia. *Semin Oncol*. 2003;30:165-8. ISSN 0093-7754.
- Cen EG, Dalton C, Li Y, **Adamia S**, Pilarski LM, Kaler KV. A combined dielectrophoresis, traveling wave dielectrophoresis and electrorotation microchip for the manipulation and characterization of human malignant cells. *J Microbiol Methods*. 2004;58:387-1. ISSN 0167-7012.

4. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, **Adamia S**, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J, Jr., Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. *Blood*. 2004;104:1151-8. ISSN 0006-4971.
5. **Adamia S**, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. *Blood*. 2005;105:4836-44. ISSN 0006-4971.
6. Pilarski LM, Lauzon J, Strachan E, **Adamia S**, Atrazhev A, Belch AR, Backhouse CJ. Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma. *J Immunol Methods*. 2005;305:94-105. ISSN 0022-1759.
7. **Adamia S***, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. *Curr Drug Targets Cardiovasc Haematol Disord*. 2005;5:3-14. ISSN 1568-0061.
8. **Adamia S***, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR, Pilarski LM. Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. *Clin Lymphoma*. 2005;5:253-6. ISSN 1526-9655.
9. Pilarski PM, **Adamia S**, Backhouse CJ. An adaptable microvalving system for on-chip polymerase chain reactions. *J Immunol Methods*. 2005;305:48-58. ISSN 0022-1759.
10. Prakash AR, **Adamia S**, Sieben V, Pilarski PM, Pilarski LM, Backhouse CJ. Small volume PCR in PDMS biochips with integrated fluid control and vapor barrier. *Sens Actuators B: Chem*. 2006;113(1):398-409. ISSN: 0925-4005.
11. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, **Adamia S**, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP. Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. *Exp Hematol*. 2007;35:1366-75. ISSN 0301-472X.
12. VanDijken J, Kaigala GV, Lauzon J, Atrazhev A, **Adamia S**, Taylor BJ, Reiman T, Belch AR, Backhouse CJ, Pilarski LM. Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts. *J Mol Diagn*. 2007;9:358-367. ISSN 1525-1578.
13. **Adamia S**, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. *Blood*. 2008;112:5111-5121. ISSN 1528-0020.
14. Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, **Adamia S**, Stone R, Galinsky I, Kung AL, Griffin JD. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. *Mol Cancer Ther*. 2008;7:1121-29. ISSN 1535-7163.
15. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, **Adamia S**, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. *Br J Haematol*. 2009;145:59-63. ISSN 1365-2141.
16. **Adamia S***, Pilarski PM, Belch AR, Pilarski LM. Genetic abnormalities in Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma*. 2009;9:30-2. ISSN 1557-9190.
17. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, **Adamia S**, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. *J Clin Oncol*. 2009;27:250-5. ISSN 1527-7755.
18. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos



- DD, **Adamia S**, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. *Blood*. 2009;113:626-634. ISSN 1528-0020.
19. Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, **Adamia S**, Kung AL, Gray NS, Griffin JD. Discovery and characterization of novel mutant FLT3 kinase inhibitors. *Mol Cancer Ther*. 2010;9:2468-77. ISSN 1538-8514.
 20. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, **Adamia S**, Wu C, Gray N, Griffin JD. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. *Blood*. 2010;115:4206-16. ISSN 1528-0020.
 21. Weisberg E, Deng X, Choi HG, Barrett R, **Adamia S**, Ray A, Moreno D, Kung AL, Gray N, Griffin JD. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. *Leukemia*. 2010;24:1375-78. ISSN 1476-5551.
 22. Weisberg E, Ray A, Nelson E, **Adamia S**, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. *PLoS One*. 2011;6:e25351. ISSN 1932-6203.
 23. Jakubikova J, **Adamia S**, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujovala D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. *Blood*. 2011;117:4409-19. ISSN 1528-0020.
 24. Amin SB, Shah PK, Yan A, **Adamia S**, Minvielle S, Avet-Loiseau H, Munshi NC, Li C. The dChip survival analysis module for microarray data. *BMC Bioinformatics*. 2011;12:72. ISSN 1471-2105.
 25. **Adamia S***, Pilarski PM, Belch AR, Pilarski LM. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets. *Curr Cancer Drug Targets*. 2013;13:347-61. ISSN 1873-5576.
 26. **Adamia S***, Pilarski PM, Bar-Natan M, Stone RM and Griffin JD. Alternative Splicing in Chronic myeloid Leukemia (CML): a novel therapeutic target? *Current cancer drug targets*, 2013 Jul 30 [Epub ahead of print]. ISSN 1873-5576.
 27. **Adamia S***, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD. A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. *Clin Cancer Res*. 2014 Feb 11. [Epub ahead of print] PMID: 24284058.
 28. **Adamia S***, Bar-Natan M*, Haibe-Kains B*, Pilarski PM*, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone RM and Griffin JD. NOTCH2 and FLT3 gene mis-splicing are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. *Blood*, 2014 Feb 26. PMID:24574459.
 29. Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, **Adamia S**, Belch AR, Pilarski LM. Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not breast cancer. *PLoS One*. 2014 Jun 20;9(6): e100691. doi: 10.1371/journal.pone.0100691.
 30. Cagnetta A, **Adamia S**, Acharya C, Patrone F, Miglino M, Nencioni A, Gobbi M, Cea M. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. *Leuk Res*. 2014 Mar 18. PMID: 24726781.

31. **Adamia S***, Kriangkum J, Belch AR, and Pilarski LM. Aberrant post-transcriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression. *Adv Cancer Res.* 2014; 123:67-94. doi: 10.1016/B978-0-12-800092-2.00003-4. PMID:25081526.
32. Cea M, Cagnetta A, **Adamia S**, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. *Blood.* 2015 Dec 16. pii: blood-2015-06-649970. [Epub ahead of print] PubMed PMID: 26675349.
33. Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, **Adamia S**, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. *Clin Cancer Res.* 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11. PubMed PMID: 25964294.
34. Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, **Adamia S**, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. *Leukemia.* 2015 Jul 23. doi: 10.1038/leu.2015.194. [Epub ahead of print] PubMed PMID: 26202935.
35. Cea M, Cagnetta A, **Adamia S**, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. *Blood.* 2015 Dec 16. pii: blood-2015-06-649970. PMID: 26675349.
36. Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, **Adamia S**, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. *Leukemia.* 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13. PMID:26165234.
37. Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, **Adamia S**, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi NC. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. *Blood Cancer J.* 2016 Jan 15;6: e380. doi: 10.1038/bcj.2015.106. PubMed PMID: 26771806; PubMed Central PMCID: PMC4742623.
38. Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, **Adamia S**, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q. Characterization of selective and potent PI3K δ inhibitor (PI3KDIN-015) for B-Cell malignances. *Oncotarget.* 2016 Apr 12. doi: 10.18632/oncotarget.8702. [Epub ahead of print] PubMed PMID: 27081697.
39. Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, **Adamia S**, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, and Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. *Nat Chem Biol.* 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2. PubMed PMID: 28967922.
40. Brunner AM, Neuberg D, Wander SA, Sadrzadeh H, Ballen K, Amrein P, Attar E, Hobbs G, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, **Adamia S**, Borger DR, Iafrate A, Graubert TA, Stone RM, and Fathi AT. Isocitrate Dehydrogenase 1 and 2 Mutations, 2-Hydroxyglutarate Levels, and Response to Standard Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia. *Cancer.* 2018 Nov 13. doi: 10.1002/ncr.31729. PMID:30422308.



41. Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, **Adamia S**, Dubreuil P, Letard S, Griffin JD. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. *Br J Haematol.* 2019;187(4):488-501.
42. **Adamia S**, Abiatari I, **Amin SB**, Fulciniti M, **Minvielle S**, **Li C**, Moreau P, **Avet-Loiseau H**, **Munshi NC**, and **Anderson CA**. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. *Leukemia.* 2020;34(1):167-179. doi: 10.1038/s41375-019-0498-5. PMID: 31182781
43. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Toure AA, Buhrlage S, Liu X, Wang J, Gray N, Stone R, **Adamia S**, Winer E, Sattler M, Griffin JD. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. *J Cell Mol Med.* 2020;24(3):2145-2156.
44. Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, **Adamia S**, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Inhibition of the deubiquitinase USP10 induces degradation of SYK. *Br J Cancer.* 2020;122(8):1175-1184.
45. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, **Adamia S**, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. *J Cell Mol Med.* 2020;24(5):2968-2980.
46. Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, **Adamia S**, Griffin JD. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. *Leukemia.* 2020;34(2):625-629.
47. Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, **Adamia S**, Ando K, Hideshima T, Anderson KC. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. *Blood.* 2020;136(20):2334-2345.
48. Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, **Adamia S**, Zhu H, Kuang Y, Mogili A, Louissaint A, Jr., Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. *Cancer Cell.* 2020;38(6):872-890 e876.
49. **Adamia S***, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso M, Abiatari I, Letai A, Dorfman D Hideshima T, and Anderson KC*. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. *Leukemia*, 2022 Jan 27. doi: 10.1038/s41375-021-01475-z. PMID: 35082402.
50. Ogiya D[#], Chyra Z[#], Verselis SJ, O'Keefe M, Cobb J, Abiatari I, Sithara AA, Hideshima T, Chu MP, Hájek R, Dorfman DM, Pilarski LM, Anderson KC* and **Adamia S***. Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. *Blood Cancer J*, 2023 Feb 3;13(1):23. Doi:1038/s41408-023-00791-0. PMID: 36737429

Reviews, chapters, monographs and editorials

1. Dalton C, **Adamia S**, Pilarski LM, and Kaler KVIS. Investigation of human malignant cells by electrorotation. In proceeding of: Electrical Insulation and Dielectric Phenomena, 2004. CEIDP '04. 2004 ISBN: 0-7803-8584-8585.
2. Pilarski LM, **Adamia S**, Maxwell CA, Pilarski PM, Reiman T, Belch AR. Editors: Balazs EA and Hascall VC. "Hyaluronan Synthases and RHAMM as Synergistic Mediators of Malignancy in B Lineage Cancers." in "Hyaluronan: Structure, Metabolism, Biological Activities, Therapeutic Applications", Chapter 4, pages 329-338, Editors: E.A. Balazs and V.C. Hascall, Matrix Biology Institute, Edgewater, New Jersey, USA, 2005.
3. Pilarski LM, **Adamia S**, Pilarski PM, Prakash R, Lauzon J, Backhouse CJ. Editors: Badawy, W. and Moussa, W. Improved Diagnosis and Monitoring of Cancer Using Portable Microfluidics Platforms. Proceedings of the International Conference on MEMS, Nano and Smart Systems, 2004. pp 340-345.